14:53:13 Europe / Stockholm

Prenumeration

Kalender

2025-01-15 Kvartalsrapport 2025-Q1
2025-01-15 Årsstämma 2025
2024-10-09 Bokslutskommuniké 2024
2024-07-10 Kvartalsrapport 2024-Q3
2024-04-10 Kvartalsrapport 2024-Q2
2024-01-11 Ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 Årsstämma 2024
2024-01-10 Kvartalsrapport 2024-Q1
2023-10-11 Bokslutskommuniké 2023
2023-07-14 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
2021-12-10 14:00:00

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the oncology portfolio with the addition of Lapatinib. Lapatinib is a targeted cancer drug, also known by its brand name Tyverb®, that is used to treat certain type of breast cancers, whose tumours overexpress HER2.

“Lapatinib is a terrific supplement to the existing high-value product portfolio and we are proud to further strengthen our commitment within oncology” says Mr Lars Minor CEO of Newbury
 
Newbury currently has eleven (11) products within oncology and providing treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer, NSCLC and thyroid cancer).
 
Regulatory filling will take place during the next few years, and we aim to be among the first to launch many of these medicines in Scandinavia where the total annual value of this market is estimated to be 400 MEUR according to DLMI Nordic Pharma Insights.
 
”Newbury is a start-up with high ambitions and  we are rapidly growing our portfolio within our focus areas of oncology, rare diseases and neurology. We want to be known to make a difference within these therapeutic areas” says Karl Karlsson Founder & Chairman